<PAGE> 1
------------------------------
OMB APPROVAL
------------------------------
OMB Number: 3235-0287
Expires: December 31, 2001
Estimated average burden
hours per response ....... 0.5
------------------------------
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 4
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or
Section 30(f) of the Investment Company Act of 1940
[_] Check this box if no longer subject to Section 16. Form 4 or Form 5
obligations may continue. See Instruction 1(b)
(Print or Type Responses)
________________________________________________________________________________
1. Name and Address of Reporting Person*
Formela Jean-Francois
--------------------------------------------------------------------------------
(Last) (First) (Middle)
222 Berkeley Street, Suite 1950
--------------------------------------------------------------------------------
(Street)
Boston, Massachusetts 02116
--------------------------------------------------------------------------------
(City) (State) (Zip)
--------------------------------------------------------------------------------
2. Issuer Name and Ticker or Trading Symbol
deCODE genetics, Inc. ("DCGN")
--------------------------------------------------------------------------------
3. I.R.S Identification Number of Reporting Person, if an entity (Voluntary)
--------------------------------------------------------------------------------
4. Statement for Month/Year
July, 2000
--------------------------------------------------------------------------------
5. If Amendment, Date of Original (Month/Year)
August 8, 2000
================================================================================
6. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
[xx] Director [__] 10% Owner
[__] Officer (give title below) [__] Other (specify below)
--------------------------------------------------------------------------------
7. Individual or Joint/Group Filing (Check Applicable Line)
[xx] Form filed by One Reporting Person
[__] Form filed by More than One Reporting Person
--------------------------------------------------------------------------------
================================================================================
TABLE I -- NON-DERIVATIVE SECURITIES ACQUIRED, DISPOSED OF,
OR BENEFICIALLY OWNED
================================================================================
<TABLE>
<CAPTION>
6.
5. Owner-
4. Amount of ship
2. 3. Securities Acquired (A) or Securities Form: 7.
Transaction Transaction Disposed of (D) Beneficially Direct Nature of
Date Code (Instr. 3, 4 and 5) Owned at End (D) or Indirect
1. (Month/ (Instr. 8) -------------------------- of Month Indirect Beneficial
Title of Security Day/ ------------ (A) or (Instr. 3 (I) Ownership
(Instr. 3) Year Code V Amount (D) Price and 4) (Instr.4) (Instr. 4)
------------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C>
Atlas
Venture
Common Stock 7/21/00 C 1,042,541 A 1,042,541 I(1) Fund II, L.P.
------------------------------------------------------------------------------------------------------------------------------------
Atlas
Venture
Europe
Common Stock 7/21/00 C 1,042,541 A 1,042,541 I(1) Fund B.V.
------------------------------------------------------------------------------------------------------------------------------------
Common Stock 7/17/00 P 5,000 A $18 5,000 D
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
====================================================================================================================================
</TABLE>
Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.
* If the form is filed by more than one Reporting Person, see Instruction
4(b)(v).
Potential persons who are to respond to the collection of information contained
in this form are not required to respond unless the form displays a currently
valid OMB Number.
(Over)
SEC 1474 (3-99)
<PAGE> 2
FORM 4 (CONTINUED)
Table II -- DERIVATIVE SECURITIES ACQUIRED, DISPOSED OF, OR BENEFICIALLY OWNED
(e.g., PUTS, CALLS, WARRANTS, OPTIONS, CONVERTIBLE SECURITIES)
================================================================================
<TABLE>
<CAPTION>
10.
9. Owner-
Number ship
of Form
Deriv- of
Conver- 5. 7. ative Deriv- 11.
ion Number of Title and Amount Secur- ative Nature
or Derivative 6. of Underlying 8. ities Secur- of
1. Exer- 4. Securities Date Securities Price Bene- ity: In-
Title ise 3. Trans- Acquired (A) Exercisable and (Instr. 3 and 4) of ficially Direct direct
of Deri Price Trans- action or Disposed Expiration Date --------------- Deriv- Owned (D)or Bene-
vate 0f action Code of(D) (Month/Day/Year) Amount ative at End In- ficial
Secur Deriv- Date (Instr. (Instr. 3, ---------------- or Secur- of direct Owner-
ity ative (Month/ 8) 4 and 5) Date Expira- Number ity Month (I) ship
(inst. Secur- Day/ ---- ------------ Exer- tion of (Instr. (Instr. (Instr. (Instr.
3) ity Year) Code V (A) (D) cisable Date Title Shares 5) 4) 4) 4)
------------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C>
Series A Preferred Common Atlas
7/21/00 C 1,042,541 Immed Stock 1,042,541 -0- I(1) Ven-
ture
Fund
II, L.P.
------------------------------------------------------------------------------------------------------------------------------------
Series A Preferred Common Atlas
7/21/00 C 1,042,541 Immed Stock 1,042,541 -0- I(1) Ven-
ture
Europe
Fund
B.V.
------------------------------------------------------------------------------------------------------------------------------------
Atlas
Ven-
Warrant(2) ture
Common Fund
10/30/97 8/26/05 Stock 125,000 $1.00 125,000 I(1) II, L.P.
------------------------------------------------------------------------------------------------------------------------------------
Atlas
Warrant(2) Ven-
Common ture
10/30/97 8/26/05 Stock 125,000 $1.00 125,000 I(1) Europe
Fund
B.V.
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
====================================================================================================================================
</TABLE>
Explanation of Responses:
(1) The reporting person is a general partner of Atlas Venture Associates, L.P.,
which is sole general partner of Atlas Venture Fund II, L.P. Atlas Venture
Europe Fund B.V. is a wholly owned subsidiary of Atlas InvesteringsGroep
N.V., which is a limited partner in Atlas Venture Fund II, L.P. The
reporting person disclaims beneficial ownership of the reported securities
except to the extent of his pecuniary interest therein.
(2) Upon closing of Issuer's public offering on July 21, 2000, the warrants
exercisable for Series A Preferred Stock became exercisable for Common
Stock.
/s/ Jean-Francois Formela 8/8/00
--------------------------------------------- -----------------------
**Signature of Reporting Person Date
** Intentional misstatements or omissions of facts constitute Federal
Criminal Violations.
See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed.
If space is insufficient, see Instruction 6 for procedure.
Potential persons who are to respond to the collection of Information contained
in this form are not required to respond unless the form displays a currently
valid OMB control number.
Page 2
